Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmacyclics

Full company profile

uuid000dqkt

Namestring
Pharmacyclics
Legal namestring
Pharmacyclics LLC
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Pharmacyclics LLC is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and a wholly-owned subsidiary of AbbVie following a 2015 acquisition valued at approximately $21 billion. The company focuses on discovering and developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with its core technology centered on Bruton's tyrosine kinase (BTK) inhibition through ibrutinib. Pharmacyclics operates one of the most robust clinical oncology development programs for a single molecule in the industry, having sponsored more than 50 clinical trials including 18 Phase 3 studies over 11 years. Its primary commercial product, IMBRUVICA (ibrutinib), is approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in previously treated pediatrics.

The company also collaborates on venetoclax (VENCLYXTO), a Bcl-2 inhibitor approved for CLL in combination regimens. Its primary customer segments are patients with hematologic malignancies and immune-mediated diseases, the oncologists and hematologists who prescribe IMBRUVICA, and clinical researchers participating in investigator-initiated studies. Pharmacyclics generates revenue indirectly through AbbVie's global commercial infrastructure, distributing IMBRUVICA via retail, hospital, and specialty pharmacies under prescription. The company supplements its commercial offering with the IMBRUVICA by Your Side patient support program, a medical information portal, and a Medical Education Grants Program covering CLL, Waldenstrom's Macroglobulinemia, and cGVHD. As a private subsidiary, Pharmacyclics does not disclose standalone financial results; its revenues are consolidated into AbbVie's reporting, with no information available on segment-level revenue, pricing, or churn metrics.

Short descriptiontext

Pharmacyclics is an AbbVie-owned biopharmaceutical subsidiary developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with IMBRUVICA (ibrutinib) as its primary approved product across CLL, MCL, WM, MZL, FL, and cGVHD indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematology oncology drugs, BTK inhibitor therapy, lymphoma treatment, immune-mediated disease therapy, biopharmaceutical research
Industry1 code
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hematology Oncology Pharmaceuticals
Social media profiles1 record
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IMBRUVICA
Description

Ibrutinib - Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström's Macroglobulinemia, marginal zone lymphoma, and chronic graft-versus-host disease.

pharmacyclics.com
Core offering1 text field

Pharmacyclics develops and commercializes IMBRUVICA (ibrutinib), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple hematologic malignancies including CLL/SLL, MCL, WM, MZL, FL, cGVHD, and pediatric mature B-cell non-Hodgkin lymphomas. The company also participates in the development of venetoclax (VENCLYXTO), a Bcl-2 inhibitor for CLL. Distribution occurs through AbbVie's pharmaceutical commercial infrastructure via healthcare provider prescriptions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pharmacyclics is an AbbVie company that develops and commercializes cancer and immune-mediated disease treatments. The company's primary product is IMBRUVICA (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, supplemented by patient support programs and medical education initiatives. The company operates one of the most robust clinical oncology development programs for a single molecule, with over 50 company-sponsored clinical trials including 18 Phase 3 studies. Key therapeutic areas include chronic lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), and chronic graft-versus-host disease (cGVHD).

Product and service2 records
1IMBRUVICA (ibrutinib)
CategoryPrescription Oncology Drug
Description

Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in pediatrics. Prescribed by oncologists and hematologists.

2Venetoclax (VENCLYXTO)
CategoryPrescription Oncology Drug
Description

Bcl-2 inhibitor developed in collaboration, approved for CLL treatment in combination regimens. Used by oncologists and hematologists for chronic lymphocytic leukemia therapy.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Pharmacyclics is a wholly-owned subsidiary of AbbVie, headquartered in the Bay Area. AbbVie acquired Pharmacyclics in 2015. Pharmacyclics operates under AbbVie's corporate structure while maintaining its brand identity and focus on oncology and immunology. All legal, privacy, and corporate governance references point to AbbVie as the parent entity.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major oncology incumbent with hematology assets (e.g., Bosulif, Mektovi) that address the same prescriber base of hematologists treating CLL and other B-cell malignancies.

TypeBroad incumbent
Description

Competes in B-cell hematologic malignancies via its Kite cell therapy franchise (Yescarta, Tecartus) and Trodelvy in ADC oncology. Same treating-physician customer base as IMBRUVICA.

TypeDirect peer
Description

Markets Calquence (acalabrutinib), a second-generation BTK inhibitor that directly competes with IMBRUVICA in CLL and other B-cell malignancies. Highly comparable mechanism, indication overlap, and customer base.

TypeBroad incumbent
Description

Pharmacyclics' parent company and the acquirer in the 2015 ~$21B deal. AbbVie is the broader specialty pharma incumbent that owns and commercializes the IMBRUVICA franchise.

TypeOthers
Description

Historically co-developed and co-promoted IMBRUVICA with Pharmacyclics / AbbVie. Compares as a legacy commercialization partner in the same BTK franchise and a broader oncology competitor.

TypeDirect peer
Description

Markets Brukinsa (zanubrutinib), a next-generation BTK inhibitor approved across multiple B-cell malignancies. Direct competitor to IMBRUVICA in CLL, MCL, MZL, WM, and FL.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Major oncology player with a hematology portfolio (e.g., Revlimid, Reblozyl, Pomalyst) overlapping the same customer base of hematologists treating CLL, MDS, and other blood cancers.

TypeBroad incumbent
Description

Major oncology and hematology player with therapies in CLL and B-cell malignancies (e.g., Kymriah, Scemblix). Comparable institutional customer base and indication overlap.

TypeBroad incumbent
Description

Global oncology leader with a broad hematology and lymphoma franchise (including Rituxan legacy and Polivy). Comparable customer base of oncologists and hematologists treating B-cell malignancies.

TypeDirect peer
Description

Markets Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor acquired via the Loxo transaction. Competes in the same BTK inhibitor class and hematology indications as Pharmacyclics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmacyclics

Hematology Oncology Pharmaceuticalspharmacyclics.com

Pharmacyclics is an AbbVie-owned biopharmaceutical subsidiary developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with IMBRUVICA (ibrutinib) as its primary approved product across CLL, MCL, WM, MZL, FL, and cGVHD indications.

What Pharmacyclics does

Pharmacyclics LLC is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and a wholly-owned subsidiary of AbbVie following a 2015 acquisition valued at approximately $21 billion. The company focuses on discovering and developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with its core technology centered on Bruton's tyrosine kinase (BTK) inhibition through ibrutinib. Pharmacyclics operates one of the most robust clinical oncology development programs for a single molecule in the industry, having sponsored more than 50 clinical trials including 18 Phase 3 studies over 11 years. Its primary commercial product, IMBRUVICA (ibrutinib), is approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in previously treated pediatrics.

The company also collaborates on venetoclax (VENCLYXTO), a Bcl-2 inhibitor approved for CLL in combination regimens. Its primary customer segments are patients with hematologic malignancies and immune-mediated diseases, the oncologists and hematologists who prescribe IMBRUVICA, and clinical researchers participating in investigator-initiated studies. Pharmacyclics generates revenue indirectly through AbbVie's global commercial infrastructure, distributing IMBRUVICA via retail, hospital, and specialty pharmacies under prescription. The company supplements its commercial offering with the IMBRUVICA by Your Side patient support program, a medical information portal, and a Medical Education Grants Program covering CLL, Waldenstrom's Macroglobulinemia, and cGVHD. As a private subsidiary, Pharmacyclics does not disclose standalone financial results; its revenues are consolidated into AbbVie's reporting, with no information available on segment-level revenue, pricing, or churn metrics.

Pharmacyclics firmographics

Firmographics
Name
Pharmacyclics
Legal name
Pharmacyclics LLC
Website
https://pharmacyclics.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Pharmacyclics is an AbbVie-owned biopharmaceutical subsidiary developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with IMBRUVICA (ibrutinib) as its primary approved product across CLL, MCL, WM, MZL, FL, and cGVHD indications.
Ownership category
akta.pro rank

Pharmacyclics industry classification

Industry
Product category
Hematology Oncology Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)

Keywords

  • Hematology oncology drugs
  • BTK inhibitor therapy
  • Lymphoma treatment
  • Immune-mediated disease therapy
  • Biopharmaceutical research

Where Pharmacyclics is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pharmacyclics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Distribution channels1 record

Marketing channels5 records

Pharmacyclics product offering

Product offering

Core offering

Pharmacyclics develops and commercializes IMBRUVICA (ibrutinib), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple hematologic malignancies including CLL/SLL, MCL, WM, MZL, FL, cGVHD, and pediatric mature B-cell non-Hodgkin lymphomas. The company also participates in the development of venetoclax (VENCLYXTO), a Bcl-2 inhibitor for CLL. Distribution occurs through AbbVie's pharmaceutical commercial infrastructure via healthcare provider prescriptions.

Product overview

Pharmacyclics is an AbbVie company that develops and commercializes cancer and immune-mediated disease treatments. The company's primary product is IMBRUVICA (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, supplemented by patient support programs and medical education initiatives. The company operates one of the most robust clinical oncology development programs for a single molecule, with over 50 company-sponsored clinical trials including 18 Phase 3 studies. Key therapeutic areas include chronic lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), and chronic graft-versus-host disease (cGVHD).

Differentiator

Problem solved

Functional benefit

Brands

  • IMBRUVICA: Ibrutinib - Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström's Macroglobulinemia, marginal zone lymphoma, and chronic graft-versus-host disease.

Products and services

  • IMBRUVICA (ibrutinib) Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in pediatrics. Prescribed by oncologists and hematologists.
  • Venetoclax (VENCLYXTO) Bcl-2 inhibitor developed in collaboration, approved for CLL treatment in combination regimens. Used by oncologists and hematologists for chronic lymphocytic leukemia therapy.

Companies that use Pharmacyclics

Customer profile

Segments3 records

Ideal customer profiles2 records

Pharmacyclics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pharmacyclics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AbbViecoreOthersPharmacyclics is a wholly-owned subsidiary of AbbVie, headquartered in the Bay Area. AbbVie acquired Pharmacyclics in 2015. Pharmacyclics operates under AbbVie's corporate structure while maintaining its brand identity and focus on oncology and immunology. All legal, privacy, and corporate governance references point to AbbVie as the parent entity.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Pharmacyclics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Major oncology incumbent with hematology assets (e.g., Bosulif, Mektovi) that address the same prescriber base of hematologists treating CLL and other B-cell malignancies.
  • Gilead Sciences: Competes in B-cell hematologic malignancies via its Kite cell therapy franchise (Yescarta, Tecartus) and Trodelvy in ADC oncology. Same treating-physician customer base as IMBRUVICA.
  • AbbVie: Pharmacyclics' parent company and the acquirer in the 2015 ~$21B deal. AbbVie is the broader specialty pharma incumbent that owns and commercializes the IMBRUVICA franchise.
  • Bristol-Myers Squibb: Major oncology player with a hematology portfolio (e.g., Revlimid, Reblozyl, Pomalyst) overlapping the same customer base of hematologists treating CLL, MDS, and other blood cancers.
  • Novartis: Major oncology and hematology player with therapies in CLL and B-cell malignancies (e.g., Kymriah, Scemblix). Comparable institutional customer base and indication overlap.
  • Roche: Global oncology leader with a broad hematology and lymphoma franchise (including Rituxan legacy and Polivy). Comparable customer base of oncologists and hematologists treating B-cell malignancies.

Direct peers

  • AstraZeneca: Markets Calquence (acalabrutinib), a second-generation BTK inhibitor that directly competes with IMBRUVICA in CLL and other B-cell malignancies. Highly comparable mechanism, indication overlap, and customer base.
  • BeiGene: Markets Brukinsa (zanubrutinib), a next-generation BTK inhibitor approved across multiple B-cell malignancies. Direct competitor to IMBRUVICA in CLL, MCL, MZL, WM, and FL.
  • Eli Lilly: Markets Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor acquired via the Loxo transaction. Competes in the same BTK inhibitor class and hematology indications as Pharmacyclics.

Others

  • Johnson & Johnson: Historically co-developed and co-promoted IMBRUVICA with Pharmacyclics / AbbVie. Compares as a legacy commercialization partner in the same BTK franchise and a broader oncology competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Pharmacyclics social profiles

Digital presence

Pharmacyclics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmacyclics leadership team

Management profile

Number of profiles

Profiles5 records

Pharmacyclics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmacyclics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmacyclics

What does Pharmacyclics do?

Pharmacyclics develops and commercializes IMBRUVICA (ibrutinib), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple hematologic malignancies including CLL/SLL, MCL, WM, MZL, FL, cGVHD, and pediatric mature B-cell non-Hodgkin lymphomas. The company also participates in the development of venetoclax (VENCLYXTO), a Bcl-2 inhibitor for CLL. Distribution occurs through AbbVie's pharmaceutical commercial infrastructure via healthcare provider prescriptions.

Is Pharmacyclics a public or private company?

Pharmacyclics is a private company. It is classified as corporate owned and is currently operating.

When was Pharmacyclics founded?

Pharmacyclics was founded in 1991. It employs 501 to 1,000 people.

Where is Pharmacyclics based?

Pharmacyclics is headquartered in Sunnyvale, United States, in the North America region.

Who are Pharmacyclics's main competitors?

Broad incumbents on record are Pfizer, Gilead Sciences, AbbVie, Bristol-Myers Squibb, Novartis and Roche. Direct peers are AstraZeneca, BeiGene and Eli Lilly. Johnson & Johnson is listed as an others.

Does Pharmacyclics have an API?

No public API is recorded for Pharmacyclics.

What industry is Pharmacyclics in?

Pharmacyclics's product category is Hematology Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesThis Legendary Billionaire Biotech Investor Has Remained A Mystery—Until NowWayne Rothbaum, a biotech investor, sold his Pharmacyclics stake early, missing out on $700 million as the company's drug became Imbruvica. He later founded cancer drug companies, including one that earned him $2.8 billion.GlobeNewswireOncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCLOncternal Therapeutics announced a collaboration with Pharmacyclics to supply ibrutinib for its Phase 3 trial ZILO-301, which tests zilovertamab plus ibrutinib in relapsed or refractory mantle cell lymphoma. The agreement supports the planned initiation of ZILO-301 in Q3 2022 and also covers the open-label companion study ZILO-302.PR NewswireChina Ibrutinib Market Report 2021: Sales Value of Ibrutinib in China is 1823% from 2017 to 2020 - Forecast to 2025A market research report on China's Ibrutinib market shows sales value increased from CNY 48,600 in 2017 to CNY 345.5 million in 2020, representing a 1823% CAGR, with 2020 growth slowing to 38.2% due to COVID-19. Pharmacyclics Inc was the only manufacturer in the Chinese Ibrutinib market in 2020, with its drug IMBRUVICA first launched in China in 2017. The report forecasts recovery growth from 2021 to 2025 driven by price reductions, market expansion, and potential inclusion of additional approved indications in the national medical insurance catalog.PR NewswireIMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)Pharmacyclics (subsidiary of Johnson & Johnson) has submitted a supplemental New Drug Application to the U.S. FDA seeking to expand the IMBRUVICA label for Waldenström's Macroglobulinemia based on over five years of follow-up data from the Phase 3 iNNOVATE trial. The submission includes data from patients treated with IMBRUVICA in combination with rituximab. The drug has been used to treat approximately 5,300 WM patients in the U.S. and nearly 200,000 patients across all approved indications.PR NewswireExtended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)AbbVie announced extended follow-up results from the Phase 3 E1912 clinical study showing superior progression-free survival and overall survival with IMBRUVICA (ibrutinib) plus rituximab compared to standard chemoimmunotherapy (FCR) in previously untreated chronic lymphocytic leukemia patients aged 70 or younger. At a median follow-up of 48 months, the IMBRUVICA arm demonstrated a 61% reduction in risk of disease progression or death and a 66% reduction in risk of death compared to the FCR arm. The study results served as the basis for a supplemental New Drug Application submitted to the U.S. FDA to expand the IMBRUVICA label, with additional long-term data from the RESONATE and RESONATE-2 trials also presented at the ASH Annual Meeting.PR NewswireIMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term follow-up results from two pivotal Phase 3 studies of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia, presented at ASCO and EHA conferences. The RESONATE study at 65.3-month median follow-up showed sustained progression-free survival benefit with IMBRUVICA versus ofatumumab (44.1 months vs 8.1 months), while RESONATE-2 at five-year follow-up demonstrated 70% PFS estimate versus 12% for chlorambucil and 83% overall survival rate. IMBRUVICA, jointly developed and commercialized by Janssen Biotech and Pharmacyclics LLC (an AbbVie company), is a BTK inhibitor with over 140,000 patients treated worldwide.PR NewswireU.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic LeukemiaThe U.S. FDA approved IMBRUVICA (ibrutinib) in combination with obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, making it the first non-chemotherapy combination regimen for this patient population. The approval was based on Phase 3 iLLUMINATE trial data showing a 77% reduction in risk of progression or death compared to chlorambucil plus obinutuzumab. This marks IMBRUVICA's tenth FDA approval since its 2013 launch, with the drug jointly developed and commercialized by Janssen Biotech and Pharmacyclics LLC, an AbbVie company.PR NewswireBringing Light To The Darkness Of Cancer: The Leukemia & Lymphoma Society's Powerful Partners Are Saving LivesThe Leukemia & Lymphoma Society's Light The Night fundraising campaign continues to beat growth records, with national companies serving as sponsors across 140 evening walks in the US and Canada. Burlington Stores continues as the #1 National Corporate Partner for the 17th consecutive year, having raised over $32 million over 16 years, while other partners including Pharmacyclics, Janssen, Walgreens, and Wawa contribute as sponsors. The United Food and Commercial Workers union, LLS's longest-standing partner since 1982, has raised $86 million to support blood cancer research and patient access to treatments.PR NewswireU.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström's Macroglobulinemia, a Rare Blood CancerThe U.S. FDA approved IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia, a rare blood cancer, making it the first approved non-chemotherapy combination regimen for this disease. The approval was based on the Phase 3 iNNOVATE study showing an 80% reduction in risk of disease progression or death with the combination therapy versus rituximab alone, with 30-month progression-free survival rates of 82% versus 28%. The expanded label marks the ninth FDA approval for IMBRUVICA since 2013, a drug jointly developed and commercialized by Janssen Biotech and Pharmacyclics (an AbbVie company).PR NewswirePhase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)AbbVie announced positive Phase 2 CAPTIVATE data on IMBRUVICA plus VENCLEXTA in previously-untreated CLL/SLL, with 77% of the first 30 patients achieving responses with no detectable minimal residual disease after six cycles. The first 14 patients completing 12 cycles had MRD negativity in 93% of peripheral blood and 86% of bone marrow samples.